Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression.

@article{Wisel2009PharmacologicalPO,
  title={Pharmacological preconditioning of mesenchymal stem cells with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine) protects hypoxic cells against oxidative stress and enhances recovery of myocardial function in infarcted heart through Bcl-2 expression.},
  author={Sheik Wisel and Mahmood Khan and Muthulakshmi L Kuppusamy and Iyyapu Krishna Mohan and Simi M. Chacko and Brian K. Rivera and Benjamin Chih-An Sun and K{\'a}lm{\'a}n Hideg and Periannan Kuppusamy},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2009},
  volume={329 2},
  pages={543-50}
}
Stem cell transplantation is a possible therapeutic option to repair ischemic damage to the heart. However, it is faced with a number of challenges including the survival of the transplanted cells in the ischemic region. The present study was designed to use stem cells preconditioned with trimetazidine (1-[2,3,4-trimethoxybenzyl]piperazine; TMZ), a widely used anti-ischemic drug for treating angina in cardiac patients, to increase the rate of their survival after transplantation. Bone marrow… CONTINUE READING